Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: An analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial

Circulation

Volumn 126, Issue 19, 2012, Pages 2309-2316

  Van Spall, Harriette G C ^a   Wallentin, Lars ^b   Yusuf, Salim ^a   Eikelboom, John W ^a   Nieuwlaat, Robby ^a   Yang, Sean ^a   Kabali, Conrad ^a   Reilly, Paul A ^c   Ezekowitz, Michael D ^d   Connolly, Stuart J ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UPPSALA UNIVERSITY   (Sweden)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

atrial fibrillation; outcomes assessment; quality improvement; warfarin

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; WARFARIN;

AFRICA; AGED; ALGORITHM; ANTICOAGULANT THERAPY; ASIA; AUSTRALIA; BLEEDING; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; EMBOLISM; EUROPE; FEMALE; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NORTH AMERICA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SOUTH AMERICA;

AGED; ALGORITHMS; ANTICOAGULANTS; ATRIAL FIBRILLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EMBOLISM; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; INTERNATIONALITY; MALE; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RISK FACTORS; STROKE; TREATMENT OUTCOME; WARFARIN;

EID: 84868589319     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.101808     Document Type: Review

References (21)

1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-67. (Pubitemid 351650486)
2. Jones M, McEwan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart. 2005;91:472-77. (Pubitemid 40432773)
3. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ; RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376:975-983.
4. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S; ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008; 118:2029-2037.
5. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, Albers GW. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med. 2007;167:239-45.
6. Ansell J, Hirsh J, Hylek E. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008;133:160S-98S. (Pubitemid 351892967)
7. van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest. 2006;129:1155-66.
8. Manotti C, Moia M, Palareti G Pengo V, Ria L, Dettori AG. Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated Program for Oral Anticoagulant Treatment). Haematologica. 2001;86:1060-70. (Pubitemid 33031872)
9. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361: 1139-1151.
10. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236-9. (Pubitemid 23069000)
11. Austin PC, Tu JV, Alter DA. Comparing hierarchical modeling with traditional logistic regression analysis among patients hospitalized with acute myocardial infarction: should we be analyzing cardiovascular outcomes data differently? Am Heart J. 2003;145:27-35. (Pubitemid 36034494)
12. Chang WC, Midodzi WK, Westerhout CM, Boersma E, Cooper J, Barnathan ES, Simoons ML, Wallentin L, Ohman EM, Armstrong PW. Are international differences in the outcomes of acute coronary syndromes apparent or real? A multilevel analysis. J Epidemiol Community Health. 2005;59:427-33. (Pubitemid 40559207)
13. Merlo J, Ostergren P-O, Broms K, Bjorck-Linne A, Liedholm H. Survival after initial hospitalization for heart failure: a multi-level analysis of patients in Swedish acute care hospitals. J Epidemiol Community Health. 2001;55:323-329. (Pubitemid 32336971)
14. Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. John Wily & Sons, Inc: Hoboken, NJ; 2004:92.
15. World Health Organization. World Health Report 2000: Health Systems: Improving Performance. Statistical annex. Geneva: World Health Organization; 2001.
16. Killip S, Mahfoud Z, Pearce K. What is an intracluster correlation coefficient? Crucial concepts for primary care researchers. Ann Fam Med. 2004;2:204-208. (Pubitemid 39317998)
17. Hernan MA, Hernandez-Diaz S, Werler MM, Mitchell AA. Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology. Am J Epidemiol. 2002;155:176-84. (Pubitemid 34072741)
18. Robinson WS. Ecological correlations and the behavior of individuals. American Sociological Review. 1950;15:351-357.
19. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e152S-e184S.
20. Kaatz S. Determinants and measures of quality in oral anticoagulation therapy. J Thromb Thrombolysis. 2008;25:61-6.
21. Kim YK, Nieuwlaat R, Connolly SJ, Schulman S, Meijer K, Raju N, Kaatz S, Eikelboom JW. Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study. J Thromb Hemost. 2010;8:101-106.